



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2023-24/135

December 15, 2023

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Intimation under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Clarification on article published in the Economic Times

Dear Sir/Madam,

Please find enclosed Company Statement in response to media article published in the Economic Times on December 15, 2023, titled “**Biocon Weighs Sale of \$1.5.b Generic API Biz**”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776

Encl: Company Statement



NOTIFICATION TO STOCK EXCHANGE

Company Statement

in response to media article on 'Biocon Weighs Sale of API Business'

Biocon is neither Evaluating Any Divestment Options for Its APIs Business nor Consulting any Bankers.

Bengaluru, Karnataka, India, December 15, 2023

"The Company is neither evaluating any divestment options for its APIs business nor consulting any bankers for this.

The story published in Economic Times today, with the headline, "*Biocon Weighs Sale of \$1.5.b Generic API Biz*" is baseless and speculative.

The API business is a strategic business segment of Biocon Limited and a key growth driver for the Company's small molecules business.

Biocon continues to strengthen this business and has an ongoing investment of over half a billion dollars in CAPEX and R&D.

The Company has a strong pipeline of niche fermentation-based APIs, peptides and high potent API products for the near- and long-term growth of its integrated APIs and Generic Formulations business." – *Company Spokesperson*

For more information:seema.ahuja@biocon.com